Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Avoiding Hazards of Bypass Surgery

By HospiMedica staff writers
Posted on 07 Sep 2005
A study of a new drug that may block the most deadly of the responses to the heart-lung machine during coronary bypass surgery is being conducted by surgeons at the Medical College of Georgia (MCG, Augusta, USA).

The response helps to prevent infection but it can also cause clotting, which results in serious complications in 7-10% of patients. More...
These complications include injury of the lung or kidney and heart attack or stroke. Children are at special risk, especially those with complex heart defects who spend hours or even days on the heart-lung machine.

"It's a massive physiologic insult like a major trauma, so our body comes alive with an inflammatory response to circulating through this unit,” explained Dr. Landolfo, chief of the MCG section of cardiothoracic surgery.

MCG is participating in a study of 5,000 heart bypass patients in about 40 states and three foreign countries that includes at-risk patients such as those who have had a previous stroke or heart attack or have diabetes. The purpose is to determine whether giving the complement blocker pexelizumab intravenously before, during, and after bypass can block the worst aspect of the inflammatory response. Women can be of risk simply because their smaller size causes their blood to pass through the machine more times. Children with low oxygen levels before surgery may have trouble activating a natural mechanism that could correct some cell damage caused by bypass surgery.

Surgeons at MCG are measuring levels of a surface receptor called CD 163 in newborns before, during, and after surgery and looking at the expression of macrophages in heart tissue. They are also looking at the complement system activated by bypass, which in children can cause leaking of endothelial cells, and at expression of factors that regulate immunity, such as NFkappaBeta.

"We are pretty good at having patients survive, but it's all the morbidity related to heart surgery. Much of what remains is related to the heart-lung machine,” observed Dr. Landolfo.




Related Links:
Medical College of Georgia

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Half Apron
Demi
Surgical Headlight
IsoTorch
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.